This number allows the product to be legally sold in Canada while its submitted license application awaits review by Health Canada.
Triarco Industries (Wayne, NJ) announced that its patented Aminogen enzyme ingredient has been granted an exemption number by Health Canada. This number allows the product to be legally sold in Canada while its submitted license application awaits review by Health Canada.
Under Canada’s Natural Health Products Regulation, dietary supplements must have a product license number or an exemption number in order to be sold in Canada. Products are granted exemption numbers only after they have undergone an initial assessment and have been determined to meet safety, quality, and efficacy criteria.
Triarco says that unpublished preclinical studies and published studies have been done to determine Aminogen’s safety and toxicity guidelines. Moreover, it says, earlier this year Health Canada’s Natural Health Products Directorate cited a clinical study done on Aminogen as being “one of only two studies available to support fungal proteolytic enzyme dosing guidelines.”
“This [exemption number from Health Canada] also reflects well on Aminogen in other international markets,” says Triarco president Rodger Rohde Jr. “People are paying attention to which products are approved for sale under the new Canadian regulations.”
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.